liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Jahnson, Staffan
Alternative names
Publications (10 of 32) Show all publications
Aljabery, F., Shabo, I., Olsson, H., Gimm, O. & Jahnson, S. (2017). Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study.. BJU International, 120(3), 329-336
Open this publication in new window or tab >>Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer: a prospective clinical study.
Show others...
2017 (English)In: BJU International, ISSN 1464-4096, E-ISSN 1464-410X, Vol. 120, no 3, p. 329-336Article in journal (Refereed) Published
Abstract [en]

OBJECTIVES: To investigate the possibility of detecting sentinel lymph nodes (SNs) in patients with urinary bladder cancer (BCa) intra-operatively and whether the histopathological status of the identified SNs reflected that of the lymphatic field.

PATIENTS AND METHODS: We studied 103 patients with BCa pathological stage T1-T4 who were treated with cystectomy and pelvic lymph node (LN) dissection during 2005-2011 at the Department of Urology, Linköping University Hospital. Radioactive tracer Nanocoll 70 MBq and blue dye were injected into the bladder wall around the primary tumour before surgery. SNs were detected ex vivo during the operation with a handheld Geiger probe (Gamma Detection System; Neoprobe Corp., Dublin, OH, USA). All LNs were formalin-fixed, sectioned three times, mounted on slides and stained with haematoxylin and eosin. An experienced uropathologist evaluated the slides.

RESULTS: The mean age of the patients was 69 years, and 80 (77%) were male. Pathological staging was T1-12 (12%), T2-20 (19%), T3-48 (47%) and T4-23 (22%). A mean (range) number of 31 (7-68) nodes per patient were examined, totalling 3 253 nodes. LN metastases were found in 41 patients (40%). SNs were detected in 83 of the 103 patients (80%). Sensitivity and specificity for detecting metastatic disease by SN biopsy (SNB) varied between LN stations, with average values of 67% and 90%, respectively. LN metastatic density (LNMD) had a significant prognostic impact; a value of ≥8% was significantly related to shorter survival. Lymphovascular invasion (LVI) occurred in 65% of patients (n = 67) and was significantly associated with shorter cancer-specific survival (P < 0.001).

CONCLUSION: We conclude that SNB is not a reliable technique for peri-operative localization of LN metastases during cystectomy for BCa; however, LNMD has a significant prognostic value in BCa and may be useful in the clinical context and in BCa oncological and surgical research. LVI was also found to be a prognostic factor.

Place, publisher, year, edition, pages
Wiley-Blackwell Publishing Inc., 2017
Keywords
#BladderCancer, #blcsm, cystectomy, lymph node metastasis, prognostic factors, sentinel node
National Category
Surgery
Identifiers
urn:nbn:se:liu:diva-136947 (URN)10.1111/bju.13700 (DOI)000407781500011 ()27797436 (PubMedID)
Note

Funding agencies: County Council of Ostergotland, Linkoping, Sweden

Available from: 2017-05-01 Created: 2017-05-01 Last updated: 2018-05-03
Thorstenson, A., Hagberg, O., Ljungberg, B., Liedberg, F., Jancke, G., Holmäng, S., . . . Jahnson, S. (2016). Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer. Scandinavian journal of urology, 50(4), 292-297
Open this publication in new window or tab >>Gender-related differences in urothelial carcinoma of the bladder: a population-based study from the Swedish National Registry of Urinary Bladder Cancer
Show others...
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 4, p. 292-297Article in journal (Refereed) Published
Abstract [en]

AbstractObjective: The aim of this investigation was to describe tumour characteristics, treatments and survival in patients with urinary bladder cancer (UBC) in a national population-based cohort, with special reference to gender-related differences. Material and methods: All primary UBC patients with urothelial pathology reported to the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) from 1997 to 2011 were included in the study. Groups were compared regarding tumour, node, metastasis classification, primary treatment and survival. Results: In total, 30,310 patients (74.9% male, 25.1% female) with UBC were analysed. A larger proportion of women than men had stage T2?T4 (p?<?0.001), and women also had more G1 tumours (p?<?0.001). However, compared to women, a larger proportion of men with carcinoma in situ or T1G3 received intravesical treatment with bacillus Calmette?Guérin or intravesical chemotherapy, and a larger proportion of men with stage T2?T4 underwent radical cystectomy (38% men vs 33% women, p?<?0.0001). The cancer-specific survival at 5 years was 77% for men and 72% for women (p?<?0.001), and the relative survival at 5 years was 72% for men and 69% for women (p?<?0.001). Conclusions: In this population-based cohort comprising virtually all patients diagnosed with UBC in Sweden between 1997 and 2011, female gender was associated with inferior cancer-specific and relative survival. Although women had a higher rate of aggressive tumours, a smaller proportion of women than men received optimal treatment.

Place, publisher, year, edition, pages
Taylor & Francis, 2016
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-126663 (URN)10.3109/21681805.2016.1158207 (DOI)000379024000009 ()27002743 (PubMedID)
Available from: 2016-04-01 Created: 2016-04-01 Last updated: 2018-03-20
Jahnson, S., Hosseini Aliabad, A., Holmang, S., Jancke, G., Liedberg, F., Ljungberg, B., . . . Rosell, J. (2016). Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment. Scandinavian journal of urology, 50(1), 14-20
Open this publication in new window or tab >>Swedish National Registry of Urinary Bladder Cancer: No difference in relative survival over time despite more aggressive treatment
Show others...
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 1, p. 14-20Article in journal (Refereed) Published
Abstract [en]

Objective. The aim of this study was to use the Swedish National Registry of Urinary Bladder Cancer (SNRUBC) to investigate changes in patient and tumour characteristics, management and survival in bladder cancer cases over a period of 15 years. Materials and methods. All patients with newly detected bladder cancer reported to the SNRUBC during 1997-2011 were included in the study. The cohort was divided into three groups, each representing 5 years of the 15 year study period. Results. The study included 31,266 patients (74% men, 26% women) with a mean age of 72 years. Mean age was 71.7 years in the first subperiod (1997-2001) and 72.5 years in the last subperiod (2007-2011). Clinical T categorization changed from the first to the last subperiod: Ta from 45% to 48%, T1 from 21.6% to 22.4%, and T2-T4 from 27% to 25%. Also from the first to the last subperiod, intravesical treatment after transurethral resection for T1G2 and T1G3 tumours increased from 15% to 40% and from 30% to 50%, respectively, and cystectomy for T2-T4 tumours increased from 30% to 40%. No differences between the analysed subperiods were found regarding relative survival in patients with T1 or T2-T4 tumours, or in the whole cohort. Conclusions. This investigation based on a national bladder cancer registry showed that the age of the patients at diagnosis increased, and the proportion of muscle-invasive tumours decreased. The treatment of all tumour stages became more aggressive but relative survival showed no statistically significant change over time.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2016
Keywords
Bladder cancer; population-based; survival
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-124469 (URN)10.3109/21681805.2015.1085089 (DOI)000367832000004 ()26382667 (PubMedID)
Available from: 2016-02-02 Created: 2016-02-01 Last updated: 2017-11-30
Jancke, G., Rosell, J. & Jahnson, S. (2016). Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence. Scandinavian journal of urology, 50(1), 33-38
Open this publication in new window or tab >>Tumour location adjacent to the ureteric orifice in primary Ta/T1 bladder cancer is predictive of recurrence
2016 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 50, no 1, p. 33-38Article in journal (Refereed) Published
Abstract [en]

Objective: The aim of this study was to evaluate tumour growth located around the ureteric orifice (LUO) at primary diagnosis of Ta/T1 urinary bladder cancer in relation to effects on recurrence and progression. Materials and methods: Clinical and pathological characteristics of patients diagnosed with primary Ta/T1 urinary bladder cancer from 1992 to 2007 were recorded prospectively. Location of the primary tumour and growth around the ureteric orifice (within 1 cm) were recorded and correlated with recurrence and progression during further follow-up. Hazard ratios (HRs) were estimated using Cox regression with 95% confidence intervals (CIs) in both univariate and multivariate analysis. Results: The study included 768 evaluable patients with a median follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Growth of a primary tumour adjacent to the ureteric orifice was associated with recurrence (HR = 1.28, 95% CI = 1.07-1.54) but not progression (HR = 1.04, 95% CI = 0.65-1.67). The most common location of the first recurrence was the posterior bladder wall (29%). Other locations in the bladder did not predict recurrence or progression. Additional factors affecting recurrence were tumour size greater than 15mm, T1 tumour category, multiplicity, malignant or missing/not representative bladder wash cytology and surgery performed by residents. Conclusions: A primary tumour located around the ureteric orifice was predictive of recurrence, which could be taken into account in future follow-up schedules.

Place, publisher, year, edition, pages
TAYLOR & FRANCIS LTD, 2016
Keywords
Bladder cancer; recurrence; tumour location; ureteric orifice
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-124470 (URN)10.3109/21681805.2015.1066849 (DOI)000367832000007 ()26202687 (PubMedID)
Available from: 2016-02-02 Created: 2016-02-01 Last updated: 2017-11-30
Hemdan, T., Malmström, P.-U., Jahnson, S. & Segersten, U. (2015). Emmprin expression predicts response and survival following cisplatin containing chemotherapy for bladder cancer: A validation study. Journal of Urology, 194(6), 1575-1581
Open this publication in new window or tab >>Emmprin expression predicts response and survival following cisplatin containing chemotherapy for bladder cancer: A validation study
2015 (English)In: Journal of Urology, ISSN 0022-5347, E-ISSN 1527-3792, Vol. 194, no 6, p. 1575-1581Article in journal (Refereed) Published
Abstract [en]

Purpose Neoadjuvant chemotherapy before cystectomy is recommended. To our knowledge the subset of patients likely to benefit has not been identified. We validate emmprin and survivin as markers of chemotherapy response. Materials and Methods Tumor specimens were obtained before therapy from a total of 250 patients with T1-T4 bladder cancer enrolled in 2 randomized trials comparing neoadjuvant chemotherapy before cystectomy with a surgery only arm. Protein expression was determined by immunohistochemistry. Results Expression was categorized according to predefined cutoffs reported in the literature. Data were analyzed with the Kaplan-Meier method and Cox models. Patients in the chemotherapy cohort with negative emmprin expression had significantly higher down staging overall survival than those with positive expression (71% vs 38%, p <0.001). The values for cancer specific survival were 76% and 56%, respectively (p <0.027). In the cystectomy only cohort emmprin expression was not associated with overall survival (46% vs 35%, p = 0.23) or cancer specific survival (55% vs 51%, p = 0.64). Emmprin negative patients had an absolute risk reduction of 25% in overall survival (95% CI 11-40) and a number needed to treat of 4 (95% CI 2.5-9.3). Survivin expression was not useful as a biomarker in this study. Limitations were the retrospective design and heterogeneity coupled with the time difference between the trials. Conclusions Patients with emmprin negative tumors have a better response to neoadjuvant chemotherapy before cystectomy than those with positive expression. © 2015 American Urological Association Education and Research, Inc.

Place, publisher, year, edition, pages
Elsevier, 2015
Keywords
antigens, biological markers, CD147, cystectomy, drug therapy, urinary bladder neoplasms, CD147 antigen, cisplatin, doxorubicin, methotrexate, survivin, adult, Article, bladder cancer, cancer adjuvant therapy, cancer patient, cancer specific survival, cancer surgery, cancer survival, controlled study, female, human, immunohistochemistry, intermethod comparison, major clinical study, male, multiple cycle treatment, overall survival, priority journal, protein expression, randomized controlled trial, retrospective study, risk reduction, treatment response, validation study
National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-126666 (URN)10.1016/j.juro.2015.06.085 (DOI)000365985900012 ()26119672 (PubMedID)2-s2.0-84947230630 (Scopus ID)
Available from: 2016-04-01 Created: 2016-04-01 Last updated: 2018-03-23
Liedberg, F., Hagberg, O., Holmang, S., Hosseini Aliabad, A., Jancke, G., Ljungberg, B., . . . Jahnson, S. (2015). Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scandinavian journal of urology, 49(4), 290-295
Open this publication in new window or tab >>Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study
Show others...
2015 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 49, no 4, p. 290-295Article in journal (Refereed) Published
Abstract [en]

Objective. The aim of this study was to investigate recurrence and progression of non-muscle-invasive bladder cancer (NMIBC) in a large population-based setting. Materials and methods. Patients with bladder cancer (stage Ta, T1 or carcinoma in situ) diagnosed in 2004-2007 (n = 5839) in Sweden were investigated 5 years after diagnosis using a questionnaire. Differences in time to recurrence and progression were analysed in relation to age, gender, tumour stage and grade, intravesical treatment, healthcare region, and hospital volume of NMIBC patients (stratified in three equally large groups). Results. Local bladder recurrence and progression occurred in 50 and 9% of the patients, respectively. The rate of local recurrence was 56% in the southern healthcare region compared to 37% in the northern region. A multivariate Cox proportional hazards model, adjusting for age, gender, tumour stage and grade, intravesical treatment, healthcare region and hospital volume, showed that recurrence was associated with TaG2 and T1 disease, no intravesical treatment and treatment in the southern healthcare region, but indicated a lower risk of recurrence in the northern healthcare region. Adjusting for the same factors in a multivariate analysis suggested that increased relative risk of progression correlated with older age, higher tumour stage and grade, and diagnosis in the Uppsala/Orebro healthcare region, whereas such risk was decreased by intravesical treatment (relative risk 0.72, 95% confidence interval 0.55-0.93, p = 0.012). Conclusions. The incidence of NMIBC recurrence and progression was found to be high in Sweden, and important disparities in outcome related to care patterns appear to exist between different healthcare regions.

Place, publisher, year, edition, pages
Informa Healthcare, 2015
Keywords
Bladder cancer; non-muscle-invasive; progression; recurrence
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-120870 (URN)10.3109/21681805.2014.1000963 (DOI)000359170200004 ()25624049 (PubMedID)
Available from: 2015-08-28 Created: 2015-08-28 Last updated: 2017-12-04
Aljabery, F., Lindblom, G., Skoog, S., Shabo, I., Olsson, H., Rosell, J. & Jahnson, S. (2015). PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer.. BMC urology, 15(1), 87
Open this publication in new window or tab >>PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer.
Show others...
2015 (English)In: BMC urology, ISSN 1471-2490, Vol. 15, no 1, p. 87-Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: We studied patients treated with radical cystectomy for locally advanced bladder cancer to compare the results of both preoperative positron emission tomography/computed tomography (PET/CT) and conventional CT with the findings of postoperative histopathological evaluation of lymph nodes.

METHODS: Patients who had bladder cancer and were candidates for cystectomy underwent preoperative PET/CT using 18-fluorodeoxyglucose (FDG) and conventional CT. The results regarding lymph node involvement were independently evaluated by two experienced radiologists and were subsequently compared with histopathology results, the latter of which were reassessed by an experienced uropathologist (HO).

RESULTS: There were 54 evaluable patients (mean age 68 years, 47 [85 %] males and 7 [15 %] females) with pT and pN status as follows: < pT2-14 (26 %), pT2-10 (18 %), and > pT2-30 (56 %); pN0 37 (69 %) and pN+ 17 (31 %). PET/CT showed positive lymph nodes in 12 patients (22 %), and 7 of those cases were confirmed by histopathology; the corresponding results for conventional CT were 11 (20 %) and 7 patients (13 %), respectively. PET/CT had 41 % sensitivity, 86 % specificity, 58 % PPV, and 76 % NPV, whereas the corresponding figures for conventional CT were 41 %, 89 %, 64 %, and 77 %. Additional analyses of the right and left side of the body or in specified anatomical regions gave similar results.

CONCLUSIONS: In this study, PET/CT and conventional CT had similar low sensitivity in detecting and localizing regional lymph node metastasis in bladder cancer.

National Category
Urology and Nephrology Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-120796 (URN)10.1186/s12894-015-0080-z (DOI)000359832000001 ()26294219 (PubMedID)
Available from: 2015-08-25 Created: 2015-08-25 Last updated: 2017-05-17
Patschan, O., Holmang, S., Hosseini, A., Liedberg, F., Ljungberg, B., Malmstrom, P.-U., . . . Jahnson, S. (2015). Use of bacillus Calmette-Guerin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scandinavian journal of urology, 49(2), 127-132
Open this publication in new window or tab >>Use of bacillus Calmette-Guerin in stage T1 bladder cancer: Long-term observation of a population-based cohort
Show others...
2015 (English)In: Scandinavian journal of urology, ISSN 2168-1805, E-ISSN 2168-1813, Vol. 49, no 2, p. 127-132Article in journal (Refereed) Published
Abstract [en]

Objective. The aim of this study was to analyse the rate of use of bacillus Calmette-Guerin (BCG) at a population-based level, and the overall mortality and bladder cancer mortality due to stage T1 bladder cancer in a national, population-based register. Materials and methods. In total, 3758 patients with primary stage T1 bladder cancer, registered in the Swedish Bladder Cancer Register between 1997 and 2006, were included. Age, gender, tumour grade and primary treatment in the first 3-6 months were registered. High-volume hospitals registered 10 or more T1 tumours per year. Date and cause of death were obtained from the National Board of Health and Welfare Cause of Death Register. Results. BCG was given to 896 patients (24%). The use of BCG increased from 18% between 1997 and 2000, to 24% between 2001 and 2003, and to 31% between 2004 and 2006. BCG was given more often to patients with G3 tumours, patients younger than 75 years and patients attending high-volume hospitals. BCG treatment, grade 2 tumours and patient age younger than 75 years were associated with lower mortality due to bladder cancer. Hospital volume, gender and year of diagnosis were not related to bladder cancer mortality. However, selection factors might have affected the results since comorbidity, number of tumours and tumour size were unknown. Conclusions. Intravesical BCG is underused at a population-based level in stage T1 bladder cancer in Sweden, particularly in patients 75 years or older, and in those treated at low-volume hospitals. BCG should be offered more frequently to patients with stage T1 bladder cancer in Sweden.

Place, publisher, year, edition, pages
Informa Healthcare, 2015
Keywords
Induction; intravesical BCG; stage T1; survival; urothelial bladder cancer
National Category
Urology and Nephrology
Identifiers
urn:nbn:se:liu:diva-117226 (URN)10.3109/21681805.2014.968868 (DOI)000351395600008 ()25331368 (PubMedID)
Available from: 2015-04-22 Created: 2015-04-21 Last updated: 2017-12-04
Hemdan, T., Johansson, R., Jahnson, S., Hellström, P., Tasdemir, I. & Malmström, P.-U. (2014). 5-Year Outcome of a Randomized Prospective Study Comparing bacillus Calmette-Guerin with Epirubicin and Interferon-alpha 2b in Patients with T1 Bladder Cancer. Journal of Urology, 191(5), 1244-1249
Open this publication in new window or tab >>5-Year Outcome of a Randomized Prospective Study Comparing bacillus Calmette-Guerin with Epirubicin and Interferon-alpha 2b in Patients with T1 Bladder Cancer
Show others...
2014 (English)In: Journal of Urology, ISSN 0022-5347, E-ISSN 1527-3792, Vol. 191, no 5, p. 1244-1249Article in journal (Refereed) Published
Abstract [en]

Purpose: In a multicenter, prospectively randomized study we evaluated the 5-year outcomes of bacillus Calmette-Guerin alone compared to a combination of epirubicin and interferon-alpha 2b in the treatment of patients with T1 bladder cancer. Materials and Methods: Transurethral resection was followed by a second resection and bladder mapping. Stratification was for grade and carcinoma in situ. Followup entailed regular cystoscopy and cytology during the first 5 years. The end points assessed in this analysis were recurrence-free survival, time to treatment failure and progression, cancer specific survival and prognostic factors. Results: The study recruited 250 eligible patients. The 5-year recurrence-free survival rate was 38% in the combination arm and 59% in the bacillus Calmette-Guerin arm (p = 0.001). The corresponding rates for the other end points were not significantly different, as free of progression 78% and 77%, treatment failure 75% and 75%, and cancer specific survival 90% and 92%, respectively. The type of treatment, tumor size and tumor status at second resection were independent variables associated with recurrence. Concomitant carcinoma in situ was not predictive of failure of bacillus Calmette-Guerin therapy. An independent factor for treatment failure was remaining T1 stage at second resection. Conclusions: Bacillus Calmette-Guerin was more effective than the tested combination therapy. The currently recommended management with second resection and 3-week maintenance bacillus Calmette-Guerin entails a low risk of cancer specific death. More aggressive treatment in patients with infiltrative tumors at second resection might improve these results. In particular, concomitant carcinoma in situ was not a predictive factor for poor outcome after bacillus Calmette-Guerin therapy.

Place, publisher, year, edition, pages
Elsevier, 2014
Keywords
urinary bladder neoplasms; chemotherapy, adjuvant
National Category
Clinical Medicine
Identifiers
urn:nbn:se:liu:diva-112027 (URN)10.1016/j.juro.2013.11.005 (DOI)000335147100010 ()24231843 (PubMedID)
Available from: 2014-11-13 Created: 2014-11-13 Last updated: 2017-12-05Bibliographically approved
Jancke, G., Rosell, J. & Jahnson, S. (2014). Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. SCANDINAVIAN JOURNAL OF UROLOGY, 48(3), 276-283
Open this publication in new window or tab >>Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer
2014 (English)In: SCANDINAVIAN JOURNAL OF UROLOGY, ISSN 2168-1805, Vol. 48, no 3, p. 276-283Article in journal (Refereed) Published
Abstract [en]

Introduction: To evaluate the impact of experience in transurethral resection of bladder tumor (TUR-BT) on recurrence and progression in primary Ta/T1 urinary bladder cancer.

Methods: Clinical and pathological characteristics of patients with primary Ta/T1 urinary bladder cancer were recorded prospectively from 1992 to 2007 inclusive. Data on surgeons’ experience were categorized as follows: (a) experience by training status (residents or specialists); (b) number of TUR-BTs performed by each surgeon during the registration period, with cut-off levels at > 100, > 150, > 200, > median, and > third quartile of surgical volume; (c) lifetime high-volume surgeons (> 100 TUR-BTs). Hazard ratios (HRs) were estimated using Cox regression with 95% confidence intervals (CIs) in both univariate and multivariate analysis.

Results: The analysis included 768 evaluable patients with a median follow-up of 60 months. Recurrence was observed in 478 patients (62%) and progression in 71 (9%). Surgery was performed by residents in 100 cases and specialists in 668, with recurrence in 75 (75%) and 403 (60%) patients, and progression in 9 (9%) and 62 (9%), respectively. Surgery performed by residents was statistically associated with recurrence (HR = 0.69, 95% CI = 0.54-0.89) but not progression (HR = 0.72, 95% CI = 0.35-1.48). Surgical volume (b and c) was not found to have a significant impact on recurrence or progression in any of the analyses at the chosen cut-offs.

Conclusions: Surgical experience (specialist/resident) was a predictive factor for recurrence after TUR-BT for Ta/T1 bladder cancer. However, surgeon volume was not associated with recurrence at the chosen cut-off levels. Training programs, checklist

Place, publisher, year, edition, pages
Informa Healthcare, 2014
National Category
Clinical Medicine Surgery Cancer and Oncology
Identifiers
urn:nbn:se:liu:diva-89145 (URN)10.3109/21681805.2013.864327 (DOI)000336457500007 ()
Available from: 2013-02-22 Created: 2013-02-22 Last updated: 2015-04-01Bibliographically approved
Organisations

Search in DiVA

Show all publications